Skip to main content
Top
Published in: Endocrine 2/2022

01-02-2022 | Stroke | Original Article

Effects of low-density lipoprotein cholesterol on cardiovascular disease and all-cause mortality in elderly patients (≥75 years old)

Authors: Jiaxin Yu, Xiaokun Liu, Shuohua Chen, Yan Liu, HongMin Liu, Hongwei Zheng, Ning Yang, Shouling Wu, Yuming Li

Published in: Endocrine | Issue 2/2022

Login to get access

Abstract

Purpose

Although increased low-density lipoprotein cholesterol (LDL-C) is one of the major risk factors for the cardiovascular disease (CVD), the associations of LDL-C with CVD and all-cause mortality are unclear in elderly (≥75 years) individuals.

Methods

A total of 3674 individuals aged 75 or older underwent medical examinations at the Kailuan Group from 2006 to 2007, including 3478 males (94.67%) and 196 females (5.33%). Participants were divided into three groups based on the LDL-C level: the ideal level (LDL-C < 100 mg/dl), appropriate level (100 mg/dl ≤ LDL-C < 130 mg/dl) and elevated level (LDL-C ≥ 130 mg/dl) groups. CVD and all-cause mortality events were recorded during the follow-up period. The Cox proportional hazards regression model was applied to evaluate the effects of LDL-C on CVD and all-cause mortality events.

Results

The average follow-up time was 9.87 ± 3.60 years. After adjustment for confounding factors, the multivariate Cox proportional hazards regression model showed that the CVD risk in the elevated level group was 1.45 (95% CI, 1.08–1.95), acute myocardial infarction risk was 1.96 (95% CI, 1.19–3.24) and all-cause mortality risk was 1.18 (95% CI, 1.02–1.37) compared with those in the ideal level group. For every standard deviation increase in LDL-C levels, the CVD risk increased by 10%, acute myocardial infarction risk increased by 21% and all-cause mortality event risk increased by 4%. No association was observed between elevated LDL-C levels and the risk of stroke.

Conclusions

In the sample of older Chinese individuals investigated in the present study, elevated LDL-C levels (≥130 mg/dl) are a risk factor for CVD and all-cause mortality.
Literature
1.
go back to reference M. Zhou, H. Wang, X. Zeng, P. Yin, J. Zhu, W. Chen, X. Li, L. Wang, L. Wang, Y. Liu, J. Liu, M. Zhang, J. Qi, S. Yu, A. Afshin, E. Gakidou, S. Glenn, V.S. Krish, M.K. Miller-Petrie, W.C. Mountjoy-Venning, E.C. Mullany, S.B. Redford, H. Liu, M. Naghavi, S.I. Hay, L. Wang, C.J.L. Murray, X. Liang, Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 394, 1145–1158 (2019)CrossRef M. Zhou, H. Wang, X. Zeng, P. Yin, J. Zhu, W. Chen, X. Li, L. Wang, L. Wang, Y. Liu, J. Liu, M. Zhang, J. Qi, S. Yu, A. Afshin, E. Gakidou, S. Glenn, V.S. Krish, M.K. Miller-Petrie, W.C. Mountjoy-Venning, E.C. Mullany, S.B. Redford, H. Liu, M. Naghavi, S.I. Hay, L. Wang, C.J.L. Murray, X. Liang, Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 394, 1145–1158 (2019)CrossRef
2.
go back to reference T.A. Jacobson, M.K. Ito, K.C. Maki, C.E. Orringer, H.E. Bays, P.H. Jones, J.M. McKenney, S.M. Grundy, E.A. Gill, R.A. Wild, D.P. Wilson, W.V. Brown, National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J. Clin. Lipidol. 9, 129–169 (2015)CrossRef T.A. Jacobson, M.K. Ito, K.C. Maki, C.E. Orringer, H.E. Bays, P.H. Jones, J.M. McKenney, S.M. Grundy, E.A. Gill, R.A. Wild, D.P. Wilson, W.V. Brown, National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J. Clin. Lipidol. 9, 129–169 (2015)CrossRef
3.
go back to reference B.A. Ference, H.N. Ginsberg, I. Graham, K.K. Ray, C.J. Packard, E. Bruckert, R.A. Hegele, R.M. Krauss, F.J. Raal, H. Schunkert, G.F. Watts, J. Borén, S. Fazio, J.D. Horton, L. Masana, S.J. Nicholls, B.G. Nordestgaard, B. van de Sluis, M.R. Taskinen, L. Tokgözoglu, U. Landmesser, U. Laufs, O. Wiklund, J.K. Stock, M.J. Chapman, A.L. Catapano, Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 38, 2459–2472 (2017)CrossRef B.A. Ference, H.N. Ginsberg, I. Graham, K.K. Ray, C.J. Packard, E. Bruckert, R.A. Hegele, R.M. Krauss, F.J. Raal, H. Schunkert, G.F. Watts, J. Borén, S. Fazio, J.D. Horton, L. Masana, S.J. Nicholls, B.G. Nordestgaard, B. van de Sluis, M.R. Taskinen, L. Tokgözoglu, U. Landmesser, U. Laufs, O. Wiklund, J.K. Stock, M.J. Chapman, A.L. Catapano, Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 38, 2459–2472 (2017)CrossRef
4.
go back to reference J. Fulcher, R. O’Connell, M. Voysey, J. Emberson, L. Blackwell, B. Mihaylova, J. Simes, R. Collins, A. Kirby, H. Colhoun, E. Braunwald, J. La Rosa, T.R. Pedersen, A. Tonkin, B. Davis, P. Sleight, M.G. Franzosi, C. Baigent, A. Keech, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385, 1397–1405 (2015)CrossRef J. Fulcher, R. O’Connell, M. Voysey, J. Emberson, L. Blackwell, B. Mihaylova, J. Simes, R. Collins, A. Kirby, H. Colhoun, E. Braunwald, J. La Rosa, T.R. Pedersen, A. Tonkin, B. Davis, P. Sleight, M.G. Franzosi, C. Baigent, A. Keech, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385, 1397–1405 (2015)CrossRef
5.
go back to reference J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. Macfarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, R.G. Westendorp, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623–1630 (2002)CrossRef J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. Macfarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, R.G. Westendorp, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623–1630 (2002)CrossRef
6.
go back to reference S. Chatterji, J. Byles, D. Cutler, T. Seeman, E. Verdes, Health, functioning, and disability in older adults-present status and future implications. Lancet 385, 563–575 (2015)CrossRef S. Chatterji, J. Byles, D. Cutler, T. Seeman, E. Verdes, Health, functioning, and disability in older adults-present status and future implications. Lancet 385, 563–575 (2015)CrossRef
7.
go back to reference S.E. Vollset, E. Goren, C.W. Yuan, J. Cao, A.E. Smith, T. Hsiao, C. Bisignano, G.S. Azhar, E. Castro, J. Chalek, A.J. Dolgert, T. Frank, K. Fukutaki, S.I. Hay, R. Lozano, A.H. Mokdad, V. Nandakumar, M. Pierce, M. Pletcher, T. Robalik, K.M. Steuben, H.Y. Wunrow, B.S. Zlavog, C.J.L. Murray, Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the global burden of disease study. Lancet 396, 1285–1306 (2020)CrossRef S.E. Vollset, E. Goren, C.W. Yuan, J. Cao, A.E. Smith, T. Hsiao, C. Bisignano, G.S. Azhar, E. Castro, J. Chalek, A.J. Dolgert, T. Frank, K. Fukutaki, S.I. Hay, R. Lozano, A.H. Mokdad, V. Nandakumar, M. Pierce, M. Pletcher, T. Robalik, K.M. Steuben, H.Y. Wunrow, B.S. Zlavog, C.J.L. Murray, Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the global burden of disease study. Lancet 396, 1285–1306 (2020)CrossRef
8.
go back to reference D. Zhao, J. Liu, M. Wang, X. Zhang, M. Zhou, Epidemiology of cardiovascular disease in China: current features and implications. Nat. Rev. Cardiol. 16, 203–212 (2019)CrossRef D. Zhao, J. Liu, M. Wang, X. Zhang, M. Zhou, Epidemiology of cardiovascular disease in China: current features and implications. Nat. Rev. Cardiol. 16, 203–212 (2019)CrossRef
9.
go back to reference S. Wu, Z. Huang, X. Yang, Y. Zhou, A. Wang, L. Chen, H. Zhao, C. Ruan, Y. Wu, A. Xin, K. Li, C. Jin, J. Cai, Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city. Circ. Cardiovasc. Qual. Outcomes 5, 487–493 (2012)CrossRef S. Wu, Z. Huang, X. Yang, Y. Zhou, A. Wang, L. Chen, H. Zhao, C. Ruan, Y. Wu, A. Xin, K. Li, C. Jin, J. Cai, Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city. Circ. Cardiovasc. Qual. Outcomes 5, 487–493 (2012)CrossRef
10.
go back to reference Joint Committee Issued Chinese Guideline for the Management of Dyslipidemia in Adults, 2016 Chinese guideline for the management of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 44, 833–853 (2016) Joint Committee Issued Chinese Guideline for the Management of Dyslipidemia in Adults, 2016 Chinese guideline for the management of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 44, 833–853 (2016)
11.
go back to reference S.M. Grundy, N.J. Stone, A.L. Bailey, C. Beam, K.K. Birtcher, R.S. Blumenthal, L.T. Braun, S. de Ferranti, J. Faiella-Tommasino, D.E. Forman, R. Goldberg, P.A. Heidenreich, M.A. Hlatky, D.W. Jones, D. Lloyd-Jones, N. Lopez-Pajares, C.E. Ndumele, C.E. Orringer, C.A. Peralta, J.J. Saseen, S.C. Smith Jr., L. Sperling, S.S. Virani, J. Yeboah, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 73, e285–e350 (2018)CrossRef S.M. Grundy, N.J. Stone, A.L. Bailey, C. Beam, K.K. Birtcher, R.S. Blumenthal, L.T. Braun, S. de Ferranti, J. Faiella-Tommasino, D.E. Forman, R. Goldberg, P.A. Heidenreich, M.A. Hlatky, D.W. Jones, D. Lloyd-Jones, N. Lopez-Pajares, C.E. Ndumele, C.E. Orringer, C.A. Peralta, J.J. Saseen, S.C. Smith Jr., L. Sperling, S.S. Virani, J. Yeboah, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 73, e285–e350 (2018)CrossRef
12.
go back to reference S.M. Abdullah, L.F. Defina, D. Leonard, C.E. Barlow, N.B. Radford, B.L. Willis, A. Rohatgi, D.K. McGuire, J.A. de Lemos, S.M. Grundy, J.D. Berry, A. Khera, Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation 138, 2315–2325 (2018)CrossRef S.M. Abdullah, L.F. Defina, D. Leonard, C.E. Barlow, N.B. Radford, B.L. Willis, A. Rohatgi, D.K. McGuire, J.A. de Lemos, S.M. Grundy, J.D. Berry, A. Khera, Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation 138, 2315–2325 (2018)CrossRef
13.
go back to reference M.G. Nanna, A.M. Navar, D. Wojdyla, E.D. Peterson, The association between low-density lipoprotein cholesterol and incident atherosclerotic cardiovascular disease in older adults: results from the National institutes of health pooled cohorts. J. Am. Geriatr. Soc. 67, 2560–2567 (2019)CrossRef M.G. Nanna, A.M. Navar, D. Wojdyla, E.D. Peterson, The association between low-density lipoprotein cholesterol and incident atherosclerotic cardiovascular disease in older adults: results from the National institutes of health pooled cohorts. J. Am. Geriatr. Soc. 67, 2560–2567 (2019)CrossRef
14.
go back to reference M.B. Mortensen, B.G. Nordestgaard, Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet 396, 1644–1652 (2020)CrossRef M.B. Mortensen, B.G. Nordestgaard, Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet 396, 1644–1652 (2020)CrossRef
15.
go back to reference S.H. Kim, K.Y. Son, Association between lipoprotein cholesterol and future cardiovascular disease and mortality in older adults: a Korean Nationwide longitudinal study. Lipids Health Dis. 20, 3 (2021)CrossRef S.H. Kim, K.Y. Son, Association between lipoprotein cholesterol and future cardiovascular disease and mortality in older adults: a Korean Nationwide longitudinal study. Lipids Health Dis. 20, 3 (2021)CrossRef
16.
go back to reference G. Nilsson, J. Ohrvik, I. Lönnberg, P. Hedberg, Ten-year survival in 75-year-old men and women: predictive ability of total cholesterol, HDL-C, and LDL-C. Curr. Gerontol. Geriatr. Res. 2009, 158425 (2009)CrossRef G. Nilsson, J. Ohrvik, I. Lönnberg, P. Hedberg, Ten-year survival in 75-year-old men and women: predictive ability of total cholesterol, HDL-C, and LDL-C. Curr. Gerontol. Geriatr. Res. 2009, 158425 (2009)CrossRef
17.
go back to reference Y. Liang, D.L. Vetrano, C. Qiu, Serum total cholesterol and risk of cardiovascular and non-cardiovascular mortality in old age: a population-based study. BMC Geriatr. 17, 294 (2017)CrossRef Y. Liang, D.L. Vetrano, C. Qiu, Serum total cholesterol and risk of cardiovascular and non-cardiovascular mortality in old age: a population-based study. BMC Geriatr. 17, 294 (2017)CrossRef
18.
go back to reference L. Bathum, R. Depont Christensen, L. Engers Pedersen, P. Lyngsie Pedersen, J. Larsen, J. Nexøe, Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register study. Scand. J. Prim. Health Care 31, 172–180 (2013)CrossRef L. Bathum, R. Depont Christensen, L. Engers Pedersen, P. Lyngsie Pedersen, J. Larsen, J. Nexøe, Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register study. Scand. J. Prim. Health Care 31, 172–180 (2013)CrossRef
19.
go back to reference B. Gencer, N.A. Marston, K. Im, C.P. Cannon, P. Sever, A. Keech, E. Braunwald, R.P. Giugliano, M.S. Sabatine, Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 396, 1637–1643 (2020)CrossRef B. Gencer, N.A. Marston, K. Im, C.P. Cannon, P. Sever, A. Keech, E. Braunwald, R.P. Giugliano, M.S. Sabatine, Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 396, 1637–1643 (2020)CrossRef
20.
go back to reference R.G. Bach, C.P. Cannon, R.P. Giugliano, J.A. White, Y. Lokhnygina, E.A. Bohula, R.M. Califf, E. Braunwald, M.A. Blazing, Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 4, 846–854 (2019)CrossRef R.G. Bach, C.P. Cannon, R.P. Giugliano, J.A. White, Y. Lokhnygina, E.A. Bohula, R.M. Califf, E. Braunwald, M.A. Blazing, Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 4, 846–854 (2019)CrossRef
21.
go back to reference Y. Ouchi, J. Sasaki, H. Arai, K. Yokote, K. Harada, Y. Katayama, T. Urabe, Y. Uchida, M. Hayashi, N. Yokota, H. Nishida, T. Otonari, T. Arai, I. Sakuma, K. Sakabe, M. Yamamoto, T. Kobayashi, S. Oikawa, S. Yamashita, H. Rakugi, T. Imai, S. Tanaka, Y. Ohashi, M. Kuwabara, H. Ito, Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation 140, 992–1003 (2019)CrossRef Y. Ouchi, J. Sasaki, H. Arai, K. Yokote, K. Harada, Y. Katayama, T. Urabe, Y. Uchida, M. Hayashi, N. Yokota, H. Nishida, T. Otonari, T. Arai, I. Sakuma, K. Sakabe, M. Yamamoto, T. Kobayashi, S. Oikawa, S. Yamashita, H. Rakugi, T. Imai, S. Tanaka, Y. Ohashi, M. Kuwabara, H. Ito, Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation 140, 992–1003 (2019)CrossRef
22.
go back to reference P.R. Sinnaeve, G.G. Schwartz, D.M. Wojdyla, M. Alings, D.L. Bhatt, V.A. Bittner, C.E. Chiang, R.M.C. Flores, R. Diaz, M. Dorobantu, S.G. Goodman, J.W. Jukema, Y.U. Kim, R. Pordy, M.T. Roe, R.G. Sy, M. Szarek, H.D. White, A.M. Zeiher, P.G. Steg, Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur. Heart J. 41, 2248–2258 (2020)CrossRef P.R. Sinnaeve, G.G. Schwartz, D.M. Wojdyla, M. Alings, D.L. Bhatt, V.A. Bittner, C.E. Chiang, R.M.C. Flores, R. Diaz, M. Dorobantu, S.G. Goodman, J.W. Jukema, Y.U. Kim, R. Pordy, M.T. Roe, R.G. Sy, M. Szarek, H.D. White, A.M. Zeiher, P.G. Steg, Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur. Heart J. 41, 2248–2258 (2020)CrossRef
23.
go back to reference P. Amarenco, J.S. Kim, J. Labreuche, H. Charles, J. Abtan, Y. Béjot, L. Cabrejo, J.K. Cha, G. Ducrocq, M. Giroud, C. Guidoux, C. Hobeanu, Y.J. Kim, B. Lapergue, P.C. Lavallée, B.C. Lee, K.B. Lee, D. Leys, M.H. Mahagne, E. Meseguer, N. Nighoghossian, F. Pico, Y. Samson, I. Sibon, P.G. Steg, S.M. Sung, P.J. Touboul, E. Touzé, O. Varenne, É. Vicaut, N. Yelles, E. Bruckert, A comparison of two LDL cholesterol targets after ischemic stroke. N. Engl. J. Med. 382, 9 (2020)CrossRef P. Amarenco, J.S. Kim, J. Labreuche, H. Charles, J. Abtan, Y. Béjot, L. Cabrejo, J.K. Cha, G. Ducrocq, M. Giroud, C. Guidoux, C. Hobeanu, Y.J. Kim, B. Lapergue, P.C. Lavallée, B.C. Lee, K.B. Lee, D. Leys, M.H. Mahagne, E. Meseguer, N. Nighoghossian, F. Pico, Y. Samson, I. Sibon, P.G. Steg, S.M. Sung, P.J. Touboul, E. Touzé, O. Varenne, É. Vicaut, N. Yelles, E. Bruckert, A comparison of two LDL cholesterol targets after ischemic stroke. N. Engl. J. Med. 382, 9 (2020)CrossRef
24.
go back to reference P. Sever, I. Gouni-Berthold, A. Keech, R. Giugliano, T.R. Pedersen, K. Im, H. Wang, B. Knusel, M.S. Sabatine, M.L. O’Donoghue, LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial. Eur. J. Prev. Cardiol. (2020). https://doi.org/10.1177/2047487320902750 P. Sever, I. Gouni-Berthold, A. Keech, R. Giugliano, T.R. Pedersen, K. Im, H. Wang, B. Knusel, M.S. Sabatine, M.L. O’Donoghue, LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial. Eur. J. Prev. Cardiol. (2020). https://​doi.​org/​10.​1177/​2047487320902750​
25.
go back to reference M. Bertolotti, G. Lancellotti, C. Mussi, Management of high cholesterol levels in older people. Geriatr. Gerontol. Int. 19, 375–383 (2019)CrossRef M. Bertolotti, G. Lancellotti, C. Mussi, Management of high cholesterol levels in older people. Geriatr. Gerontol. Int. 19, 375–383 (2019)CrossRef
26.
go back to reference T.E. Strandberg, L. Kolehmainen, A. Vuorio, Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA 312, 1136–1144 (2014)CrossRef T.E. Strandberg, L. Kolehmainen, A. Vuorio, Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA 312, 1136–1144 (2014)CrossRef
27.
go back to reference F. Mach, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, M.J. Chapman, G.G. De Backer, V. Delgado, B.A. Ference, I.M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T.R. Pedersen, G. Riccardi, D.J. Richter, M.S. Sabatine, M.R. Taskinen, L. Tokgozoglu, O. Wiklund, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111–188 (2020)CrossRef F. Mach, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, M.J. Chapman, G.G. De Backer, V. Delgado, B.A. Ference, I.M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T.R. Pedersen, G. Riccardi, D.J. Richter, M.S. Sabatine, M.R. Taskinen, L. Tokgozoglu, O. Wiklund, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111–188 (2020)CrossRef
28.
go back to reference A.R. Orkaby, J.A. Driver, Y.L. Ho, B. Lu, L. Costa, J. Honerlaw, A. Galloway, J.L. Vassy, D.E. Forman, J.M. Gaziano, D.R. Gagnon, P.W.F. Wilson, K. Cho, L. Djousse, Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA 324, 68–78 (2020)CrossRef A.R. Orkaby, J.A. Driver, Y.L. Ho, B. Lu, L. Costa, J. Honerlaw, A. Galloway, J.L. Vassy, D.E. Forman, J.M. Gaziano, D.R. Gagnon, P.W.F. Wilson, K. Cho, L. Djousse, Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA 324, 68–78 (2020)CrossRef
Metadata
Title
Effects of low-density lipoprotein cholesterol on cardiovascular disease and all-cause mortality in elderly patients (≥75 years old)
Authors
Jiaxin Yu
Xiaokun Liu
Shuohua Chen
Yan Liu
HongMin Liu
Hongwei Zheng
Ning Yang
Shouling Wu
Yuming Li
Publication date
01-02-2022
Publisher
Springer US
Keyword
Stroke
Published in
Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02870-3

Other articles of this Issue 2/2022

Endocrine 2/2022 Go to the issue